Literature DB >> 12682261

Persistence of lesions in suppressor of cytokine signaling-1-deficient mice infected with Leishmania major.

Denise V R Bullen1, Tracey M Baldwin, Joan M Curtis, Warren S Alexander, Emanuela Handman.   

Abstract

To investigate the role of the cytokine IFN-gamma and its negative regulator, the suppressor of cytokine signaling-1 (SOCS1) in the progression of cutaneous leishmaniasis, we infected mice lacking a single copy of the gene encoding SOCS1 (SOCS1(+/-)), mice lacking both copies of IFN-gamma (IFN-gamma(-/-)), or mice lacking copies of both SOCS1 and IFN-gamma (SOCS1(-/-) IFN-gamma(-/-)), with a moderate dose of 10(3) or 10(4) of the most virulent stage of parasites, metacyclic promastigotes. Surprisingly, SOCS1(+/-) mice developed larger lesions than wild-type mice, although the parasite load in the draining lymph node was not significantly altered. These mice also developed apparently normal Th1 responses, as indicated by elevated levels of IFN-gamma and low levels of IL-4 and IL-10. The persistence of lesions and the enlargement of draining lymph nodes despite a normal Th1 response and control of parasitemia indicate that there may be a dissociation of the inflammatory pathology and clearance of parasites in SOCS1(+/-) mice. We also investigated the role of the related suppressor of cytokine signaling, SOCS2, which has been implicated in the development of Th1 immunity. The progression of disease in SOCS2(-/-) mice did not differ from that in C57BL/6 control mice, suggesting that it is not involved in the host response to Leishmania major infection and supporting the specific role of SOCS1. These results suggest that SOCS1 plays an important role in the regulation of appropriate inflammatory responses during the resolution of L. major infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682261     DOI: 10.4049/jimmunol.170.8.4267

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function.

Authors:  Christine Brender; Ruth Columbus; Donald Metcalf; Emanuela Handman; Robyn Starr; Nick Huntington; David Tarlinton; Niels Ødum; Sandra E Nicholson; Nicos A Nicola; Douglas J Hilton; Warren S Alexander
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

2.  Impairment of gamma interferon signaling in human neutrophils infected with Anaplasma phagocytophilum.

Authors:  Uta Bussmeyer; Arup Sarkar; Kirsten Broszat; Tanja Lüdemann; Sonja Möller; Ger van Zandbergen; Christian Bogdan; Martina Behnen; J Stephen Dumler; Friederike D von Loewenich; Werner Solbach; Tamás Laskay
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

3.  SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.

Authors:  Camille A Knosp; Helen P Carroll; Joanne Elliott; Sean P Saunders; Hendrik J Nel; Sylvie Amu; Joanne C Pratt; Shaun Spence; Emma Doran; Nicola Cooke; Ruaidhri Jackson; Jonathan Swift; Denise C Fitzgerald; Liam G Heaney; Padraic G Fallon; Adrien Kissenpfennig; James A Johnston
Journal:  J Exp Med       Date:  2011-06-06       Impact factor: 14.307

4.  Expression of suppressor of cytokine signaling 1 (SOCS1) impairs viral clearance and exacerbates lung injury during influenza infection.

Authors:  Keer Sun; Sharon Salmon; Vijaya Kumar Yajjala; Christopher Bauer; Dennis W Metzger
Journal:  PLoS Pathog       Date:  2014-12-11       Impact factor: 6.823

Review 5.  SOCS proteins in infectious diseases of mammals.

Authors:  Mario Delgado-Ortega; Daniel Marc; Joëlle Dupont; Sascha Trapp; Mustapha Berri; François Meurens
Journal:  Vet Immunol Immunopathol       Date:  2012-11-20       Impact factor: 2.046

6.  SOCS-1 inhibition of type I interferon restrains Staphylococcus aureus skin host defense.

Authors:  Nathan Klopfenstein; Stephanie L Brandt; Sydney Castellanos; Matthias Gunzer; Amondrea Blackman; C Henrique Serezani
Journal:  PLoS Pathog       Date:  2021-03-10       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.